aromasil has been researched along with Hot Flashes in 11 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 8 (72.73) | 29.6817 |
| 2010's | 3 (27.27) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Budd, GT; Chapman, JA; Ellis, MJ; Goss, PE; Ingle, JN; Kundapur, J; Le Maitre, A; Liedke, PE; Ma, CX; Pritchard, KI; Rabaglio, M; Shepherd, LE; Sledge, GW; Stearns, V | 1 |
| Charehbili, A; Fontein, DB; Kranenbarg, EM; Kroep, JR; Linn, SC; Nortier, JW; Putter, H; van de Velde, CJ | 1 |
| Ansari, RH; Budd, GT; Chalchal, H; Chapman, JA; D'Souza, DP; Elliott, C; Ellis, MJ; Gelmon, KA; Goss, PE; Ingle, JN; Johnson, DB; Lang, I; Liedke, PE; Perez, EA; Pritchard, KI; Rabaglio, M; Shepherd, LE; Sledge, GW; Spadafora, S; Stearns, V; Tozer, R | 1 |
| Fujita, Y; Inaji, H; Kanda, K; Miura, S; Nishimura, R; Saeki, H; Saeki, T; Sano, M; Sono, H; Toi, M; Watanabe, T | 1 |
| Abe, R; Andou, J; Aoyama, H; Fujita, Y; Higashi, Y; Hirata, K; Kajiwara, T; Kanda, K; Kashiki, Y; Kimura, M; Kinoshita, H; Kitajima, M; Kobayashi, T; Kobayashi, Z; Koyama, H; Koyanagi, Y; Miura, S; Miyazaki, I; Monden, M; Morishita, Y; Nagao, K; Nomura, Y; Ogita, M; Oka, T; Satomi, S; Sonoo, H; Tabei, T; Takai, S; Takashima, S; Takatsuka, Y; Toge, T; Tominaga, K; Toyama, K; Watanabe, M; Watanabe, T; Yamaguchi, S; Yayoi, E; Yoshino, K | 1 |
| Cleary, JF; Havighurst, TC; Hutson, PR; Love, RR | 1 |
| Bedaiwy, MA; Casper, RF; Mousa, NA | 1 |
| Perez, EA | 1 |
| Asmar, L; Blum, JL; Bordelon, JH; Brooks, R; Cantrell, J; Chittoor, S; Davis, JC; Hartung, NL; Holmes, FA; Ilegbodu, D; Jones, SE; Ketchel, SJ; Kochis, J; Negron, AG; O'Shaughnessy, J; Pippen, J; Richards, DA; Rivera, R; Vukelja, S; Whittaker, TL | 1 |
| Marshall, C; Thomas, R; Walker, L; Williams, M | 1 |
1 review(s) available for aromasil and Hot Flashes
| Article | Year |
|---|---|
Safety of aromatase inhibitors in the adjuvant setting.
Topics: Anastrozole; Androstadienes; Animals; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Cardiovascular Diseases; Causality; Chemotherapy, Adjuvant; Comorbidity; Estrogen Receptor Modulators; Female; Hot Flashes; Humans; Incidence; Letrozole; Neoadjuvant Therapy; Neoplasms, Hormone-Dependent; Neoplasms, Second Primary; Nitriles; Osteoporosis; Rats; Survival Analysis; Tamoxifen; Triazoles | 2007 |
8 trial(s) available for aromasil and Hot Flashes
| Article | Year |
|---|---|
Treatment-associated musculoskeletal and vasomotor symptoms and relapse-free survival in the NCIC CTG MA.27 adjuvant breast cancer aromatase inhibitor trial.
Topics: Adult; Aged; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Disease-Free Survival; Female; Hot Flashes; Humans; Kaplan-Meier Estimate; Middle Aged; Musculoskeletal System; Nitriles; Triazoles; Vasomotor System | 2015 |
Specific adverse events are associated with response to exemestane therapy in postmenopausal breast cancer patients: Results from the TEAMIIA study (BOOG2006-04).
Topics: Aged; Aged, 80 and over; Androstadienes; Aromatase Inhibitors; Arthralgia; Arthritis; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Disease-Free Survival; Female; Hot Flashes; Humans; Joint Diseases; Logistic Models; Magnetic Resonance Imaging; Mammography; Mastectomy; Middle Aged; Multivariate Analysis; Musculoskeletal Diseases; Myalgia; Neoadjuvant Therapy; Odds Ratio; Osteoporosis; Postmenopause; Prognosis; Receptors, Estrogen; Treatment Outcome; Ultrasonography, Mammary; Vasomotor System | 2017 |
Exemestane versus anastrozole in postmenopausal women with early breast cancer: NCIC CTG MA.27--a randomized controlled phase III trial.
Topics: Aged; Anastrozole; Androstadienes; Aromatase Inhibitors; Breast Neoplasms; Disease-Free Survival; Female; Follow-Up Studies; History, 18th Century; Hot Flashes; Humans; Hypercholesterolemia; Kaplan-Meier Estimate; Middle Aged; Nitriles; Osteoporosis; Postmenopause; Time Factors; Treatment Outcome; Triazoles | 2013 |
[Late phase II study of exemestane in postmenopausal patients with breast cancer resistant to anti-estrogenic agents].
Topics: Adult; Aged; Aged, 80 and over; Androstadienes; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Drug Administration Schedule; Drug Resistance, Neoplasm; Enzyme Inhibitors; Estrogen Antagonists; Estrogens; Female; Hot Flashes; Humans; Hypertension; Middle Aged; Postmenopause; Reproducibility of Results | 2002 |
[Early phase II dose-finding study of exemestane in postmenopausal patients with advanced/recurrent breast cancer].
Topics: Administration, Oral; Androstadienes; Antineoplastic Agents; Breast Neoplasms; Drug Administration Schedule; Estrogens; Female; Headache; Hot Flashes; Humans; Middle Aged; Nausea; Postmenopause; Receptors, Estrogen | 2002 |
Endocrine effects of tamoxifen plus exemestane in postmenopausal women with breast cancer.
Topics: Adult; Aged; Alkaline Phosphatase; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Cholesterol, HDL; Estradiol; Estrogen Antagonists; Estrone; Exanthema; Female; Hot Flashes; Humans; Middle Aged; Postmenopause; Tamoxifen; Treatment Outcome | 2005 |
Comparison of menopausal symptoms during the first year of adjuvant therapy with either exemestane or tamoxifen in early breast cancer: report of a Tamoxifen Exemestane Adjuvant Multicenter trial substudy.
Topics: Adult; Aged; Aged, 80 and over; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Double-Blind Method; Female; Follow-Up Studies; Hot Flashes; Humans; Menopause; Middle Aged; Quality of Life; Surveys and Questionnaires; Tamoxifen; Time Factors; Treatment Outcome | 2007 |
Switching to letrozole or exemestane improves hot flushes, mood and quality of life in tamoxifen intolerant women.
Topics: Affect; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Arthralgia; Breast Neoplasms; Chemotherapy, Adjuvant; Cross-Over Studies; Estrogen Receptor Modulators; Female; Hot Flashes; Humans; Letrozole; Middle Aged; Nitriles; Patient Participation; Patient Selection; Postmenopause; Prospective Studies; Quality of Life; Research Design; Sample Size; Surveys and Questionnaires; Tamoxifen; Triazoles | 2008 |
2 other study(ies) available for aromasil and Hot Flashes
| Article | Year |
|---|---|
Aromatase inhibitors in the treatment of severe endometriosis.
Topics: Androstadienes; Aromatase Inhibitors; Chronic Disease; Endometriosis; Estrogen Replacement Therapy; Female; Hot Flashes; Humans; Hysterectomy; Letrozole; Middle Aged; Nitriles; Pelvic Pain; Postmenopause; Treatment Outcome; Triazoles | 2007 |
Exemestane for advanced breast cancer.
Topics: Androstadienes; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Clinical Trials as Topic; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Drug Interactions; Enzyme Inhibitors; Female; Hot Flashes; Humans; Intestinal Absorption; Liver; Middle Aged; Mixed Function Oxygenases; Postmenopause | 2000 |